Last reviewed · How we verify
Pulmicort (budesonide) pMDI
Budesonide is a corticosteroid that binds to glucocorticoid receptors in the lungs to reduce inflammation and suppress immune responses in the airways.
Budesonide is a corticosteroid that binds to glucocorticoid receptors in the lungs to reduce inflammation and suppress immune responses in the airways. Used for Asthma maintenance therapy, Chronic obstructive pulmonary disease (COPD).
At a glance
| Generic name | Pulmicort (budesonide) pMDI |
|---|---|
| Sponsor | AstraZeneca |
| Drug class | Inhaled corticosteroid |
| Target | Glucocorticoid receptor |
| Modality | Small molecule |
| Therapeutic area | Respiratory / Pulmonology |
| Phase | FDA-approved |
Mechanism of action
Budesonide exerts its anti-inflammatory effects by binding to intracellular glucocorticoid receptors, which then translocate to the nucleus and modulate gene expression. This leads to decreased production of inflammatory mediators (cytokines, chemokines, adhesion molecules) and reduced recruitment of inflammatory cells to the airways. The pMDI (pressurized metered-dose inhaler) formulation delivers the drug directly to the lungs, providing local anti-inflammatory action with minimal systemic exposure.
Approved indications
- Asthma maintenance therapy
- Chronic obstructive pulmonary disease (COPD)
Common side effects
- Tremor
- Headache
- Nervousness
- Oral candidiasis
- Dysphonia
- Throat irritation
Key clinical trials
- Post-marketing Phase 4 Safety & Tolerability Study of Breztri aerosphereTM in Indian Patients With Chronic Obstructive Pulmonary Disease (PHASE4)
- A Study to Investigate How Budesonide and Formoterol Move Through the Body (Pharmacokinetics) When Delivered With Different Devices in Participants Aged 4 to Less Than 12 Years Old With Asthma (PHASE1)
- Open-label Study to Assess Reduction of Background Asthma Medication While Sustaining Asthma Control and Clinical Remission With Tezepelumab in Patients 12-80yrs With Severe Asthma. (PHASE3)
- Pressurized Meter Dose Inhaler V/S Dry Powder Inhaler (NA)
- Anti-Inflammatory Reliever South Africa (PHASE3)
- Combination Short-Acting BroNchodilator and Inhaled Corticosteroid Rescue Therapy on Health Outcomes in Routine Care (PHASE4)
- Study to Assess PT010 in Adult and Adolescent Participants With Inadequately Controlled Asthma (KALOS) (PHASE3)
- Study to Assess PT010 in Adult and Adolescent Participants With Inadequately Controlled Asthma (LOGOS) (PHASE3)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Pulmicort (budesonide) pMDI CI brief — competitive landscape report
- Pulmicort (budesonide) pMDI updates RSS · CI watch RSS
- AstraZeneca portfolio CI